Contact
News Bank
In the ceedd Media Center you can read about the latest milestones from the ceedd alliances in our news bank, discover the ceedd making headlines in "ceedd in the news," download our PDF fact sheet and contact the GSK Media Center.
View news for:
ChemoCentryx
-
June 17, 2010
ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
Read Full Story ›› - April 8, 2010
ChemoCentryx Identifies Novel Small Molecule ChemR23 Antagonist for the Treatment of Inflammatory Diseases
Read Full Story ›› - January 28, 2010
ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
Read Full Story ›› - January 11, 2010
GSK Exercises Option to Progress Development of ChemoCentryx's Traficet-EN for the Treatment of Inflammatory Bowel Diseases
Read Full Story ›› - December 16, 2009
ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
Read Full Story ›› - December 7, 2009
ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease
Read Full Story ›› - May 5, 2009
ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
Read Full Story ›› - October 15, 2008
ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 into Clinical Development
Read Full Story ›› - June 12, 2008
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN™ ) in Crohn's Disease
Read Full Story ›› - May 13, 2008
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 Drug Represents Potential New Approach for the Treatment of Inflammatory Disease
Read Full Story ›› - July 24, 2007
ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for Nomination of CCR1 Small Molecule Development Candidate
Read Full Story ›› - August 24, 2006
GlaxoSmithKline and ChemoCentryx Enter Into Drug Discovery and Development Alliance in Inflammatory Disorders
Read Full Story ››
Chroma Therapeutics
- June 23, 2009
GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs
Read Full Story ››
Concert Pharmaceuticals
- November 9, 2009
Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of CTP-518, Protease Inhibitor for Treatment of HIV
Read Full Story ›› - June 2, 2009
Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs Read Full Story ››
Ligand
- March 18, 2008
Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline
Read Full Story ›› - September 28, 2009
Ligand and GlaxoSmithKline Collaboration Identifies New Compound
Read Full Story ››
OncoMed Pharmaceuticals
- December 10, 2007
GlaxoSmithKline and OncoMed Pharmaceuticals Form Strategic Alliance to Develop Cancer Stem Cell Antibody Therapeutics
Read Full Story ››
Prosensa
-
June 23, 2010
Prosensa and GlaxoSmithKline Initiate Development of Four Additional Products under Existing Alliance in Duchenne Muscular Dystrophy
Read Full Story ›› -
March 30, 2010
Prosensa initiates clinical development of PRO044
Read Full Story ›› -
October 13, 2009
GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy
Read Full Story ››
Ranbaxy
- January 09, 2009
Ranbaxy's Drug Discovery Team Achieves Significant Landmark in GSK Research Collaboration
Read Full Story ›› - October 13, 2008
Ranbaxy Achieves Another Significant Milestone In GSK Research Collaboration
Read Full Story ››
Targacept
- May 05, 2008
Targacept Announces Designation of Lead Compound in Smoking Cessation Program
Read Full Story ›› - December 10, 2007
Targacept to Receive $6 Million from GlaxoSmithKline for Initiation of Phase I Trial of Neuropathic Pain Candidate
Read Full Story ›› - December 03, 2007
Targacept Announces Results of Phase II Study of TC-2696 in Postoperative Dental Pain
Read Full Story ›› - July 27, 2007
GlaxoSmithKline and Targacept Form Alliance in Therapeutics for CNS-related Disorders
Read Full Story ››
Theravance
- No current news
ceedd in the news
- The ceedd's alliance with Prosensa was highlighted as one of this year's most strategically interesting alliances during the EuroBiotech Fourm 2010 on June 30. Learn more about Prosensa's alliance with the ceedd in the ceedd of innovation.
- Senior Vice President, Head of ceedd Michelle Dipp selected as one of Mass High Tech's "Women to Watch" for 2010.
- The IN VIVO Blog posted an article announcing the GSK/Concert collaboration as a nominee for this year's Second Annual Deal of the Year! competition. The article calls this deal “harmonious” and “rather clever,” and highlights other successful GSK deals from 2009, including the Prosensa partnership.
